Research shows cancer drug compounds eliminate malaria parasites in laboratory cultures — Evidence Review
Published in ACS Omega, by researchers from University of São Paulo’s School of Pharmaceutical Sciences
Researched by
— the AI search engine for science
Table of Contents
Researchers at the University of São Paulo have found that compounds derived from anti-cancer drugs can kill malaria parasites in multiple life stages, potentially offering a new approach to combat malaria transmission. Related studies broadly agree that certain cancer or antiparasitic compounds can show cross-activity against malaria, supporting the promise of this new strategy (original source).
- Several prior studies have demonstrated that drugs originally developed for cancer or other diseases can have significant activity against malaria parasites, with some even showing effects on the transmission stages and offering new targets for intervention 3 5 8 9.
- The current findings align with earlier work on drug repurposing, particularly regarding compounds that act on parasite-specific enzymes or pathways, supporting the continued search for non-traditional antimalarial agents 8 9 15.
- However, concerns about toxicity, selectivity, and stability in vivo, highlighted in the new study, echo limitations and safety concerns raised by related research on drug repurposing for both malaria and cancer 1 2 4 5.
Study Overview and Key Findings
Malaria remains a global health challenge, especially as Plasmodium falciparum, the parasite responsible for most malaria deaths, develops increasing resistance to standard treatments. The need for new therapeutic strategies is urgent, particularly those that target multiple stages of the parasite's lifecycle to both treat infection and block transmission. This study focuses on testing derivatives of anti-cancer drugs for their ability to selectively kill malaria parasites not only during symptomatic infection but also at the gametocyte stage, which is critical for transmission to mosquitoes.
| Property | Value |
|---|---|
| Study Year | 2026 |
| Organization | University of São Paulo’s School of Pharmaceutical Sciences |
| Journal Name | ACS Omega |
| Authors | Bárbara K.M. Dias, Pedro N. Maiolini, Natacha Diesca Santos, Karoline B. Waitman, Mauricio T. Tavares, João P.F. Verotti, Mônica F.Z.J. Toledo, Thales Kronenberger, Roberto Parise-Filho, Célia R.S. Garcia |
| Population | Laboratory cultures of Plasmodium falciparum |
| Sample Size | 14 compounds |
| Methods | In Vitro Study |
| Outcome | Activity against malaria parasite stages |
| Results | Compounds eliminated parasites during both asexual and gametocyte stages. |
Literature Review: Related Studies
To place these findings in context, we searched the Consensus research database, which includes over 200 million academic papers. The following queries were used to identify relevant studies:
- cancer drugs malaria treatment effectiveness
- antimalarial compounds gametocyte elimination
- parasite life cycle cancer drug impact
Below is a summary table organizing key insights from the literature by major thematic questions:
| Topic | Key Findings |
|---|---|
| Can cancer or antiparasitic drugs be repurposed for malaria or vice versa? | - Several anticancer and antiparasitic drugs, such as artemisinin, chloroquine, benzimidazoles, and ivermectin, have shown activity against both cancer and malaria, often acting through multi-targeted mechanisms 1 2 4 5 11 12 15. - Drug repurposing efforts highlight the potential for crossover efficacy but also underscore the need for careful evaluation of toxicity and selectivity 1 4 5 15. |
| Are there compounds that target multiple stages of the malaria parasite—including gametocytes? | - Some compounds, including proteasome inhibitors and certain synthetic derivatives, exhibit potent activity against both asexual and sexual (gametocyte) stages of Plasmodium falciparum, potentially blocking both disease and transmission 3 7 8 9. - Most current antimalarials are less effective against mature gametocytes, emphasizing the significance of new compounds that can address this gap 6 7 8 9. |
| What are the main challenges in translating in vitro findings to clinical use? | - In vitro efficacy does not always translate to in vivo activity due to issues like drug stability, bioavailability, and toxicity; compounds such as artemisinin and derivatives have shown promise but require thorough safety studies before broader use 1 4 5. - Toxicity, degradation, and selectivity remain major hurdles for repurposed drugs, often necessitating additional optimization and rational drug design 1 4 5 15. |
| What are promising targets or pathways for dual antimalarial and anticancer activity? | - Enzymes such as histone deacetylases, the proteasome, and parasite-specific metabolic pathways are promising targets for compounds with dual activity against malaria and cancer 3 5 8 9 15. - Hybrid molecules and structure-guided drug design can enhance potency and selectivity, as observed with ferrocene-based and pyrazole acrylic acid derivatives 3 5. |
Can cancer or antiparasitic drugs be repurposed for malaria or vice versa?
A consistent theme in the literature is the exploration of drugs developed for one indication—such as cancer or parasitic diseases—for use in the other. Artemisinin, chloroquine, benzimidazoles, and ivermectin are among the compounds extensively studied for such crossover potential. The new study builds on this trend by testing antineoplastic derivatives for antimalarial activity, echoing previous findings while underscoring the complexities of selectivity and toxicity.
- Artemisinin and its derivatives, long used for malaria, have demonstrated anticancer effects in preclinical studies, though clinical translation must address safety concerns 1 4 15.
- Chloroquine, a traditional antimalarial, is also known to sensitize cancer cells to chemotherapy, illustrating the bidirectional nature of drug repurposing 2.
- Benzimidazoles and ivermectin, originally antiparasitic agents, show emerging promise as anticancer drugs, reinforcing the overlap in therapeutic targets 11 12 15.
- Drug repurposing offers a rapid route to new therapies but necessitates careful toxicity and efficacy evaluation in the context of the new indication 1 4 5 15.
Are there compounds that target multiple stages of the malaria parasite—including gametocytes?
Most antimalarial drugs are primarily effective against the asexual blood stages responsible for symptoms, with limited activity against gametocytes, the form responsible for mosquito transmission. However, recent research—including the current study—demonstrates that certain compounds can target both stages, potentially reducing both disease and transmission.
- Proteasome inhibitors and selected synthetic derivatives have shown the ability to kill both asexual and mature gametocyte stages in vitro, with some even blocking transmission in mosquito models 3 7 8 9.
- Meta-analyses of current antimalarials confirm that widely-used treatments often fail to clear gametocytes, supporting the need for new approaches that address this limitation 6.
- High-throughput screening has identified additional chemical classes with gametocytocidal activity, expanding the pool of transmission-blocking candidates 7 8.
- The ability to target multiple parasite stages is seen as a critical feature for future malaria eradication efforts 6 8 9.
What are the main challenges in translating in vitro findings to clinical use?
While many compounds show promise in cell-based assays, relatively few advance to successful clinical application. Issues such as toxicity, instability, and limited selectivity are recurring barriers, reflected in the concerns raised by the current study and echoed in the literature.
- Artemisinin and related compounds are effective but have shown hepatotoxicity in some clinical trials, illustrating the importance of comprehensive safety evaluations before combination or repurposed use 1 4.
- Many candidate drugs degrade rapidly or have poor pharmacokinetic profiles in vivo, limiting their effectiveness despite strong in vitro activity 5 15.
- Rational drug design and detailed structure-activity studies are essential to improve selectivity for the parasite over human cells, reducing adverse effects 4 5 15.
- Clinical trials and in vivo studies remain the gold standard for confirming efficacy and safety, but such studies are resource-intensive and often lag behind in vitro discoveries 1 4 5 15.
What are promising targets or pathways for dual antimalarial and anticancer activity?
The search for compounds with both antimalarial and anticancer activity has led to the identification of promising molecular targets that are essential in both parasites and cancer cells. The current study supports the role of histone deacetylase (HDAC) enzymes as a viable target for malaria treatment, consistent with prior findings.
- HDAC inhibitors, proteasome inhibitors, and compounds targeting parasite-specific enzymes have shown efficacy in killing both malaria parasites and cancer cells 3 5 8 9 15.
- Structural modification of lead compounds—such as hybridizing ferrocene with antimalarial scaffolds—can improve both potency and selectivity 3 5.
- Cheminformatic and rational design approaches facilitate the identification of druggable sites unique to the parasite, potentially reducing off-target effects in humans 8 15.
- Continued investigation of parasite-specific metabolic and signaling pathways holds promise for the development of novel dual-activity drugs 3 5 8 9 15.
Future Research Questions
While the current study contributes important insights into drug repurposing and malaria control, several unanswered questions and challenges remain. Further research is needed to translate these findings from the laboratory to real-world impact, to optimize compound selectivity and safety, and to address the diversity of malaria-causing species.
| Research Question | Relevance |
|---|---|
| How do anticancer drug derivatives perform against malaria parasites in animal models? | In vivo studies are essential to confirm whether promising in vitro efficacy and selectivity translate to effectiveness and safety in whole organisms, addressing a key limitation of current research 1 4 5. |
| What structural features of histone deacetylase inhibitors improve selectivity for Plasmodium species? | Understanding which molecular modifications enhance parasite specificity could guide rational drug design, minimizing toxicity and maximizing efficacy 4 5 8 15. |
| Can novel compounds effectively eliminate gametocytes in vivo and block malaria transmission? | Transmission-blocking is a major goal for malaria elimination, but few compounds have demonstrated robust efficacy against gametocytes in vivo 6 7 8 9. |
| How do antimalarial compounds perform against different Plasmodium species, such as P. vivax? | Plasmodium vivax presents unique challenges due to its ability to cause relapses; testing compounds across multiple species is necessary for global malaria control 6. |
| What are the long-term toxicity profiles of repurposed anticancer or antiparasitic drugs for malaria in humans? | Safety is a critical concern, particularly for drugs repurposed from cancer therapy, which may have significant adverse effects in non-cancer patients 1 4 5. |